Copy/Paste the key inputs from the product brochure, per guidance from Marketing.

The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy antihistamines, prescribed for both chronic inducible and chronic spontaneous urticaria. However, both drug classes have serious side effects, and many patients still struggle to control their lesions. As a result, the approval of Xolair has been welcomed by physicians and patients. Clinical trials for additional biological therapies are underway, capturing urticaria disease data using an array of clinical scoring systems. With only one biological drug currently approved, the most important factors for driving prescribing decisions remain unknown, and many of the unmet needs in this market remain unfulfilled.

Questions Answered

  • What is the physician perspective on steroids and antihistamines for chronic urticaria? How frequently are these therapies prescribed?
  • How do allergists and dermatologists diagnose and treat chronic urticaria, and how does treatment differ between specialists? Are inducible and spontaneous urticaria treated similarly, or is the treatment algorithm distinct?
  • Which therapies are expected to have the biggest impact on the chronic urticaria market forecast? Will emerging therapies shift the treatment algorithm, or will biologics remain later-line treatments?
  • How does Xolair (Novartis / Genentech), approved for chronic idiopathic urticaria in the United States, perform, and how will emerging biologics compare? How does its performance compare with that of frequently prescribed conventional therapies, including steroids and antihistamines?

Content Highlights

Geographies: United States, EU5, Japan.

Primary research: 18 country-specific interviews with thought-leading allergists and dermatologists supported by survey data collected for this and other DRG research.

Epidemiology: Number of chronic urticaria patients by country, including diagnosed and drug-treated patients

Forecast: 10-year, annualized, drug-level sales and patient share of key chronic urticaria therapies through 2029, segmented by brands/generics.

Emerging therapies: Phase III / PR: 3 drugs; Phase II: 3 drugs; coverage of select preclinical and Phase I products

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Urticaria - Landscape & Forecast - Disease Landscape And Forecast

Author(s): Kristine Mackin, PhD; Devashri Mukherjee, MPH

Kristine Mackin, Ph.D., is an analyst on the immune and inflammatory disorders team at Decision Resources Group. She currently focuses on respiratory diseases, including asthma and COPD.

She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins. During her B.A. in Chemistry at Carleton College, she researched proinsulin processing. Prior to joining DRG, Dr. Mackin was involved with literature and market research for a new company pitch during an internship at Puretech Ventures in Boston, MA.

Research enthusiast with a flair for academic writing, member of the DRG family since April 2015 and working from the India office.

Started off career with a bachelor’s in Dental Surgery followed by a master’s in Public health; having primarily worked in the hospital setting as a Research Consultant prior to DRG and with 10 international publications to my credit.

Related Reports

Urticaria - Unmet Need - Detailed, Expanded Analysis (US & EU) Chronic Inducible Urticaria And Chronic Spontaneous Urticaria

The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy antihistamines, prescribed for both chronic inducible and chronic spontaneous urticar...

View Details

Urticaria - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Chronic Inducible Urticaria (US)

MARKET OUTLOOKChronic inducible urticaria (CIndU) encompasses various chronic urticaria subtypes caused by specific triggers. CIndU appears to be more resistant than chronic...

View Details

Urticaria - Epidemiology - Mature Markets

DRG Epidemiology's coverage of urticaria comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy...

View Details

Urticaria | Treatment Algorithms: Claims Data Analysis | Chronic Spontaneous | US | 2020

Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria, presents as hives that persist daily or almost daily for six weeks or longer without an obvious known stimulus. Drug...

View Details